SGMT250117C12500
- 0.05
- 0.000.00%
Sagimet Biosciences Newsroom
Institutional Investors Have a Lot Riding on Sagimet Biosciences Inc. (NASDAQ:SGMT) With 43% Ownership
Express News | Sagimet Biosciences Announces Oral Presentation at the 9TH Annual Mash-Tag 2025 Conference
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Sagimet Biosciences Price Target Announced at $30.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $31
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$141m
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Institutional Investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) See US$36m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Sagimet Biosciences Analyst Ratings
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
Sagimet Biosciences Advances MASH Treatment With Denifanstat
Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating
Sagimet Biosciences | 8-K: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates